MSI-H/ MMRd
Quiénes somos
Estudio de TAS-102 más radioterapia para el tratamiento del hígado en pacientes con metástasis hepáticas de cáncer colorrectal
Estudio de fase 1/2 para evaluar CHM-2101, una terapia autóloga con células T receptoras de antígeno quimérico (CAR) de cadherina 17.
Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Estudio de fase 2 de CA102N combinado con TAS-102 comparado con bevacizumab combinado con TAS-102 en sujetos con cáncer colorrectal metastásico recidivante y/o refractario.
Estudio de CNA3103 (células CAR-T autólogas dirigidas a LGR5) administrado a sujetos con cáncer colorrectal metastásico.
RC48-ADC combinado con bevacizumab en cáncer colorrectal avanzado HER2-positivo
Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
